Biblio

Found 17 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
A. Cull, Howat, S., Greimel, E., Waldenstrom, A. C., Arraras, J., Kudelka, A., Chauvenet, L., Gould, A., Group, E. O. R. T. C. Quality of, and Group, S. Gynaecolog, Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report, Eur J Cancer, vol. 37, pp. 47-53, 2001.
C. L. Creutzberg, Kitchener, H. C., Birrer, M. J., Landoni, F., Lu, K. H., Powell, M., Aghajanian, C., Edmondson, R., Goodfellow, P. J., Quinn, M., Salvesen, H. B., Thomas, G., and Meeting, G. C. I. G. Endometria, Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era, Int J Gynecol Cancer, vol. 23, pp. 1528-34, 2013.
S. C. Crawford, Vasey, P. A., Paul, J., Hay, A., Davis, J. A., and Kaye, S. B., Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial, J Clin Oncol, vol. 23, pp. 8802-11, 2005.
N. Colombo, Parma, G., Bocciolone, L., Franchi, D., Sideri, M., and Maggioni, A., Medical therapy of advanced malignant epithelial tumours of the ovary, Forum (Genova), vol. 10, pp. 323-32, 2000.
N. Colombo, Guthrie, D., Chiari, S., Parmar, M. K. B., Qian, W., Swart, A. Marie, Torri, V., Williams, C., Lissoni, A., Bonazzi, C., and Collaborators, I. Collaborat, International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer, J Natl Cancer Inst, vol. 95, pp. 125-32, 2003.
N. Colombo, Guthrie, D., Chiari, S., Parmar, M. K. B., Qian, W., Swart, A. Marie, Torri, V., Williams, C., Lissoni, A., and Bonazzi, C., International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer., J Natl Cancer Inst, vol. 95, no. 2, pp. 125-32, 2003.
F. Collinson, Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M. K. B., Ledermann, J. A., Colombo, N., and Swart, A. Marie, Optimal treatment of early-stage ovarian cancer., Ann Oncol, vol. 25, no. 6, pp. 1165-71, 2014.
I. C. O. N. Collaborators, ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study, Lancet, vol. 352, pp. 1571-6, 1998.
A. R. Clamp, Maenpaa, J. U., Cruickshank, D. J., Ledermann, J. A., Wilkinson, P. M., Welch, R., Chan, S., Vasey, P. A., Sorbe, B., Hindley, A., and Jayson, G. C., SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer., Br J Cancer, vol. 94, no. 1, pp. 55-61, 2006.
A. R. Clamp, Maenpaa, J. U., Cruickshank, D. J., Ledermann, J. A., Wilkinson, P. M., Welch, R., Chan, S., Vasey, P. A., Sorbe, B., Hindley, A., Jayson, G. C., and Group, S. Gynaecolog, SCOTROC 2B: Feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer, Br J Cancer, vol. 94, pp. 55-61, 2006.
J. K. Chan, Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J., Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer., N Engl J Med, vol. 374, no. 8, p. 748, 2016.
A. Casado, Penninckx, B., Reed, N. Simon, van der Burg, M. E. L., Berns, E. M. J. J., Katsaros, D., Ferrero, A., Fernando, M., Jimeno, A., Vermorken, J. B., Pecorelli, S., and Vergote, I. B., EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. , European Journal Cancer , vol. 10, no. 1, p. 73, 2012.
M. S. Carey, Bacon, M., Tu, D., Butler, L., Bezjak, A., and Stuart, G. C. E., The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer., Gynecol Oncol, vol. 108, no. 1, pp. 100-5, 2008.
M. S. Carey and Gotay, C., Patient-reported outcomes: clinical trials in ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 782-7, 2011.
S. Camilleri-Broet, Hardy-Bessard, A. C., Le Tourneau, A., Paraiso, D., Levrel, O., Leduc, B., Bain, S., Orfeuvre, H., Audouin, J., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group, Ann Oncol, vol. 15, pp. 104-12, 2004.
I. Cadron, Leunen, K., Amant, F., Van Gorp, T., Neven, P., and Vergote, I. B., The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer, Gynecol Oncol, vol. 106, pp. 354-61, 2007.
L. C, Simes, R. J., Gebski, V., Wollschlaeger, K., Plante, M., Vergote, I. B., Maenpaa, J. U., Ferrero, A., Pisano, C., Parma, G., Berton-Rigaud, D., der W, S., Bentley, J., Reinthaller, A., Schmalfeldt, B., Hirte, H., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. , Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.